gamma-secretase/Notch signalling pathway inhibitor RO4929097

DRUG18 trials

Sponsors

National Cancer Institute (NCI)

Conditions

AIDS-related Diffuse Large Cell LymphomaAIDS-related Diffuse Mixed Cell LymphomaAIDS-related Diffuse Small Cleaved Cell LymphomaAIDS-related Immunoblastic Large Cell LymphomaAIDS-related Lymphoblastic LymphomaAIDS-related Peripheral/Systemic LymphomaAIDS-related Primary CNS LymphomaAIDS-related Small Noncleaved Cell Lymphoma

Phase 1

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

TerminatedNCT01088763

National Cancer Institute (NCI)Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma +43

Start: 2010-03-31End: 2011-05-31Updated: 2014-11-05

Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies

CompletedNCT01096355

National Cancer Institute (NCI)Unspecified Adult Solid Tumor, Protocol Specific

Start: 2010-02-28Updated: 2014-04-02

Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

CompletedNCT01145456

National Cancer Institute (NCI)Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer +2

Start: 2010-06-30Updated: 2014-02-24

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

CompletedNCT01158274

National Cancer Institute (NCI)Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma +83

Start: 2010-06-30Updated: 2014-11-07

RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

TerminatedNCT01189240

National Cancer Institute (NCI)Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma +3

Start: 2010-12-31End: 2015-02-28Updated: 2015-12-14

RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer

TerminatedNCT01192763

National Cancer Institute (NCI)Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer +2

Start: 2010-08-31Updated: 2013-09-30

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors

CompletedNCT01198184

National Cancer Institute (NCI)Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Renal Cell Cancer +5

Start: 2010-08-31End: 2013-10-31Updated: 2014-05-30

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

TerminatedNCT01208441

National Cancer Institute (NCI)Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer +2

Start: 2010-11-30Updated: 2013-09-30

RO4929097 in Treating Patients With Recurrent Invasive Gliomas

TerminatedNCT01269411

National Cancer Institute (NCI)Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Giant Cell Glioblastoma +4

Start: 2011-07-31Updated: 2013-02-07

Phase 2

RO4929097 in Treating Patients With Metastatic Colorectal Cancer

CompletedNCT01116687

National Cancer Institute (NCI)Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer +1

Start: 2010-05-31End: 2012-03-31Updated: 2014-05-20

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

TerminatedNCT01120275

National Cancer Institute (NCI)Acral Lentiginous Malignant Melanoma, Lentigo Maligna Malignant Melanoma, Nodular Malignant Melanoma +4

Start: 2010-10-31End: 2015-08-31Updated: 2016-06-14

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma

TerminatedNCT01122901

National Cancer Institute (NCI)Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma +1

Start: 2010-12-31End: 2015-08-31Updated: 2017-05-03

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

TerminatedNCT01151449

National Cancer Institute (NCI)Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer +7

Start: 2010-06-30End: 2015-08-31Updated: 2017-04-11

RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy

TerminatedNCT01193868

National Cancer Institute (NCI)Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer

Start: 2010-09-30End: 2014-04-30Updated: 2015-11-18

Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

TerminatedNCT01200810

National Cancer Institute (NCI)Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer

Start: 2010-08-31End: 2012-11-30Updated: 2017-12-02

RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery

WithdrawnNCT01216787

National Cancer Institute (NCI)Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma

Start: 2010-09-30Updated: 2013-01-31

Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer

CompletedNCT01232829

National Cancer Institute (NCI)Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer

Start: 2010-10-31End: 2014-05-31Updated: 2014-11-26

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

WithdrawnNCT01270438

National Cancer Institute (NCI)Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer +5

Start: 2010-12-31End: 2013-08-31Updated: 2017-04-04